We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$957M
AUM Growth
+$1.08M
Cap. Flow
-$9.87M
Cap. Flow %
-1.03%
Top 10 Hldgs %
32.99%
Holding
140
New
9
Increased
34
Reduced
55
Closed
6

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$11.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$9.5M
3
ONC
BeOne Medicines Ltd
ONC
+$9.49M
4
INCY icon
Incyte
INCY
+$8.91M
5
CELG
Celgene Corp
CELG
+$8.11M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$20.7M
2
GILD icon
Gilead Sciences
GILD
+$16.8M
3
ABMD
Abiomed Inc
ABMD
+$10.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.6M
5
ABBV icon
AbbVie
ABBV
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Financials 0.41%
3 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
76
DELISTED
Sage Therapeutics
SAGE
$2.08M 0.22%
+12,650
New +$1.23M
GMED icon
77
Globus Medical
GMED
$10.5B
$2.01M 0.21%
48,850
-6,150
-11% -$215K
HCSG icon
78
Healthcare Services Group
HCSG
$1.74B
$2M 0.21%
38,000
– –
JUNO
79
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.92M 0.2%
41,900
-1,100
-3% -$54.9K
RARE icon
80
Ultragenyx Pharmaceutical
RARE
$2.88B
$1.9M 0.2%
40,900
-1,100
-3% -$53.9K
NUVA
81
DELISTED
NuVasive, Inc.
NUVA
$1.89M 0.2%
32,312
-13,892
-30% -$788K
ABBV icon
82
AbbVie
ABBV
$450B
$1.89M 0.2%
19,500
-83,277
-81% -$7.85M
IRTC icon
83
iRhythm Holdings
IRTC
$3.64B
$1.87M 0.2%
33,400
– –
HCA icon
84
HCA Healthcare
HCA
$82.3B
$1.87M 0.2%
21,300
– –
QTRX icon
85
Quanterix
QTRX
$182M
$1.8M 0.19%
+83,800
New +$1.64M
EGRX
86
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.76M 0.18%
33,000
-48,550
-60% -$2.7M
QGEN icon
87
Qiagen
QGEN
$8.49B
$1.75M 0.18%
53,387
-4,716
-8% -$163K
ANGO icon
88
AngioDynamics
ANGO
$558M
$1.69M 0.18%
101,700
– –
TDOC icon
89
Teladoc Health
TDOC
$1.7B
$1.64M 0.17%
47,000
– –
TRHC
90
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$1.63M 0.17%
58,000
+2,593
+5% +$76K
PEN icon
91
Penumbra
PEN
$12.5B
$1.58M 0.17%
16,800
– –
HALO icon
92
Halozyme
HALO
$9.23B
$1.56M 0.16%
77,000
-10,600
-12% -$195K
MRK icon
93
Merck
MRK
$315B
$1.55M 0.16%
28,820
– –
EXEL icon
94
Exelixis
EXEL
$14.1B
$1.54M 0.16%
50,600
-1,400
-3% -$37.2K
MASI
95
DELISTED
Masimo
MASI
$1.44M 0.15%
17,000
– –
IBB icon
96
iShares Biotechnology ETF
IBB
$9.23B
$1.44M 0.15%
13,500
-13,500
-50% -$1.44M
ITCI
97
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.34M 0.14%
92,500
+52,500
+131% +$811K
CHRS icon
98
Coherus Oncology
CHRS
$216M
$1.32M 0.14%
+150,000
New +$1.61M
CYTO
99
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.28M 0.13%
27
– –
IPXL
100
DELISTED
Impax Laboratories, Inc.
IPXL
$1.25M 0.13%
75,000
-12,000
-14% -$220K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2017 Portfolio in Review

As of Q4 2017, Bellevue Group held 140 positions worth $957M, up 0.11% from $956M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group's Q4 2017 filing shows 9 new, 34 increased, 55 reduced and 6 closed positions. Its largest new stake was Supernus Pharmaceuticals: 240,400 shares worth $9.58M. The largest sale was Amgen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Group's largest Q4 2017 buy was Supernus Pharmaceuticals: 240,400 shares worth $9.58M.
  • Bellevue Group added most to DexCom in Q4 2017, an estimated $11.5M increase.
  • Bellevue Group's biggest Q4 2017 reduction was Amgen, cutting an estimated $20.7M.
  • Bellevue Group fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $8.6M.
  • Bellevue Group's ten largest holdings make up 33% of its $957M portfolio in Q4 2017.
  • Bellevue Group opened 9 new positions and closed 6 in Q4 2017.
  • Bellevue Group's portfolio value rose 0.11% quarter-over-quarter to $957M.

Based on Bellevue Group's 13F filing for Q4 2017, filed 14 Feb 2018.